Menu Search
Equities

AstraZeneca PLC

AZN:STO

AstraZeneca PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)1,384.00
  • Today's Change3.00 / 0.22%
  • Shares traded181.84k
  • 1 Year change+34.06%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2022 17:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

  • Revenue in GBP (TTM)37.34bn
  • Net income in GBP1.69bn
  • Incorporated1992
  • Employees83.10k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AZN:LSE since
announced		Transaction
value
TeneoTwo IncDeal completed05 Jul 202205 Jul 2022Deal completed1.35%1.27bn
Data delayed at least 20 minutes, as of Nov 25 2022 16:45 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.